Investors Tell 1st Circ. Sarepta Hid FDA Testing Issues
By Alison Noon ( December 4, 2017, 9:05 PM EST) -- A group of shareholders asked the First Circuit on Monday to revive their securities class action claiming executives at Sarepta Therapeutics Inc. selectively omitted facts and misled investors in 2014 about the clinical trial and regulatory outlook of a treatment for the most common form of muscular dystrophy called Duchenne....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.